Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Prostate cancer
Results 1-25 of 364 for your search:
Start Over
Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study.
Status: Active
Phase: Phase IV
Type: Treatment
Age: 18 and over
Trial IDs: CSOM230B2412, NCI-2017-01247, NCT01794793
68Ga-PSMA PET/CT in Detecting Prostate Cancer Recurrence in Patients with Elevated PSA after Initial Treatment
Status: Active
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Diagnostic
Age: Not specified
Trial IDs: PROS0076, NCI-2016-00094, 35932, NCT02673151
68Ga-PSMA PET/MRI in Finding Tumors in Patients with Intermediate or High-Risk Prostate Cancer Undergoing Surgery
Status: Active
Phase: Phase III, Phase II
Type: Diagnostic
Age: 18 and over
Trial IDs: PROS0075, NCI-2016-00092, 35931, NCT02678351
68Ga-RM2 PET/MRI in Detecting Prostate Cancer in Patients with Biochemical Recurrent and CT Scan Negative Prostate Cancer
Status: Active
Phase: Phase III, Phase II
Type: Genetics
Age: 18 and over
Trial IDs: PROS0074, NCI-2015-01993, 348, NCT02624518
Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer (OSPREY)
Status: Active
Phase: Phase III, Phase II
Type: Diagnostic
Age: 18 and over
Trial IDs: PyL 2301, NCI-2017-00029, NCT02981368
Antiandrogen Therapy and Radiation Therapy with or without Docetaxel in Treating Patients with Prostate Cancer That Has Been Removed by Surgery
Status: Active
Phase: Phase III, Phase II
Type: Treatment
Age: 18 and over
Trial IDs: NRG-GU002, NCI-2016-00963, NCT03070886
F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets
Status: Active
Phase: Phase III
Type: Diagnostic
Age: 18 and over
Trial IDs: AMI-2008-01, NCI-2014-02587, NCT00882609
Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients with Prostate Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: RTOG 0924, NCI-2011-02674, CDR0000701128, PRTOG-0924_A03PAMDREVW01, NCT01368588
Modifications to Radical Prostatectomy in Improving Outcomes in Patients with Prostate Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 21 and over
Trial IDs: 11-096, NCI-2011-02377, NCT01407263
Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: PrTK03, NCI-2012-01912, NCT01436968
A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate
Status: Active
Phase: Phase III
Type: Treatment
Age: Any age
Trial IDs: CR100797, NCI-2013-00686, 2011-005243-28, 212082PCR3010, NCT01517802
Robotic Assisted Laparoscopic Prostatectomy with or without Pelvic Drain Placement in Reducing Adverse Events after Surgery in Patients with Prostate Cancer
Status: Temporarily closed
Phase: Phase III
Type: Supportive care
Age: 18 and over
Trial IDs: 11113, NCI-2012-00558, NCT01613651
Proton Beam or Intensity-Modulated Radiation Therapy in Treating Patients with Low or Low-Intermediate Risk Prostate Cancer
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: 18 and over
Trial IDs: 11-497, NCI-2012-01144, NCT01617161
Androgen Deprivation Therapy and Orteronel or Bicalutamide in Treating Patients with Newly Diagnosed Metastatic Prostate Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: S1216, NCI-2012-02876, SWOG-S1216, NCT01809691
Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: MDV3100-14, NCI-2013-02393, NCT02003924
Phase III Study of DCVAC Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: SP005, NCI-2014-02085, 2012-002814-38, NCT02111577
Efficacy and Safety Study of BAY1841788 (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer (ARAMIS)
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 17712, NCI-2015-00347, 2013-003820-36, NCT02200614
Online Multimedia Program in Improving Coping and Function in Prostate Cancer Survivors
Status: Active
Phase: Phase III
Type: Supportive care
Age: 18 and over
Trial IDs: 11-825, NCI-2014-01941, IRB11825, NCT02224482
Surgery or Non-surgical Management in Treating Patients with Intra-abdominal Cancer and Bowel Obstruction
Status: Active
Phase: Phase III
Type: Supportive care
Age: 18 and over
Trial IDs: S1316, NCI-2014-01497, SWOG/S1316, NCT02270450
Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: MDV3100-13, NCI-2015-00824, NCT02319837
Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: ANZUP1303, NCI-2015-01658, ACTRN12614000126617, NCT02446444
Diet and Exercise Program to Promote Weight Loss and Improve Health in Men with Low- or Low-Intermediate-Risk Prostate Cancer
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care
Age: 40 to 75
Trial IDs: 9369, NCI-2015-00686, NCT02454517
Perioperative Risk Stratification and Risk-Based, Protocol-Driven Management in Reducing Death or Serious Complications in Patients with Cancer Undergoing Surgery
Status: Active
Phase: Phase III
Type: Health services research, Supportive care
Age: 18 and over
Trial IDs: 14-036, NCI-2014-02262, NCT02456389
An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CR106935, NCI-2016-00117, 2015-003007-38, 56021927PCR3003, NCT02531516
A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CR107614, NCI-2016-00191, 2015-000735-32, 56021927PCR3002, NCT02489318
Start Over